Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China

被引：0
|
作者：
Lin, Nanlong [1 ,2 ]
Chen, Shiting [3 ]
Zheng, Zhiwei [4 ]
Song, Xiaobing [5 ]
机构：
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Fuzhou, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Thorac Surg, Binhai Campus, Fuzhou, Peoples R China
[3] Fujian Med Univ, Quangang Gen Hosp, Affiliated Hosp 1, Dept Gen Surg, Quanzhou, Peoples R China
[4] Shantou Univ, Canc Hosp, Med Coll, Dept Pharm, Shantou, Guangdong, Peoples R China
[5] Ganzhou Fifth Peoples Hosp, Dept Qual Management, Ganzhou 341000, Jiangxi, Peoples R China
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2025年 / 25卷 / 02期
关键词：
Esophageal squamous cell carcinoma; cost-effectiveness; first-line treatment; sintilimab; chemotherapy; SQUAMOUS-CELL CARCINOMA; CANCER STATISTICS; PROFILES;
D O I：
10.1080/14737167.2024.2410248
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
BackgroundTo evaluate the cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of the Chinese health service system.MethodsA partitioned survival model was constructed to simulate quality-adjusted life years and incremental cost-effectiveness ratios over a patient's lifetime based on a phase III clinical trial.ResultsSintilimab plus chemotherapy increased by 0.316 QALY and 0.285 QALY with the additional cost of $5692 and $5269, which led to the ICER of $18000/QALY and $18519/QALY gained in the overall population and the patients with CPS >= 10, respectively.ConclusionsCompared with chemotherapy alone, sintilimab may be a cost-effective first-line treatment choice for locally advanced or metastatic ESCC.
引用
收藏
页码：205 / 213
页数：9
相关论文
共 50 条
  • [1] First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
    Shen, Jian
    Du, Yi
    Shao, Rong
    Jiang, Rong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Zeng, Fan-Yuan
    Tang, Zi-Qing
    Zhou, Qin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [4] Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
    Liu, Lulu
    Wang, Lei
    Chen, Li
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [6] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [7] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [8] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
  • [9] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Shijie Lu
    Yake Lou
    Yi Rong
    Zirui Huang
    Xiaodan Lin
    Junying Chen
    Kongjia Luo
    Clinical Drug Investigation, 2023, 43 : 643 - 652
  • [10] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
12345